MarketPulse
G

$GILD

11 articles found
7 positive
0 negative
4 neutral
BenzingaBenzinga··Vandana Singh

Gilead Bolsters Inflammation Arsenal With $1.675B Ouro Medicines Deal

Gilead acquires Ouro Medicines for $1.675B upfront, targeting inflammation pipeline expansion. Galapagos NV partners to co-develop lead asset OM336.
GILDACLXGLPGacquisitionorphan drug designation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Galapagos and Gilead Team Up on Breakthrough T Cell Engager for Autoimmune Diseases

Galapagos and Gilead plan to jointly develop an Ouro T cell engager for autoimmune diseases, splitting acquisition costs while Galapagos leads development and Gilead commercializes, freeing $500M in Galapagos cash.
GILDGLPGautoimmune diseasesorphan drug designation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Galapagos, Gilead in Advanced Talks on T-Cell Therapy Partnership

Galapagos and Gilead are in advanced partnership talks for a first-in-class T-cell engager for autoimmune diseases, with 50% cost-sharing and €500 million capital freed for Galapagos.
GILDGLPGstrategic partnershipclinical development
The Motley FoolThe Motley Fool··Jonathan Ponciano

Cormorant's $64M Arcellx Exit Preceded 77% Gilead Takeover Surge

Cormorant Asset Management exited its $63.63M Arcellx stake in Q4, missing an 80% year-to-date rally capped by Gilead Sciences' $7.8B acquisition announcement.
GILDACLXfund exitoncology
Investing.comInvesting.com··Nathan Reiff

Three Cash Flow Powerhouses Offer Shelter Amid Market Uncertainty

Three firms—Gilead Sciences, AbbVie, and Visa—offer defensive portfolios substantial free cash flow yields and capital returns amid 2026 market uncertainty.
VABBVGILDdividendpayments
The Motley FoolThe Motley Fool··Jake Lerch

Boxer Capital Doubles Down on TNGX With $9.5M Stake as Biotech Stock Soars

Boxer Capital invests $9.5M in clinical-stage biotech $TNGX, raising stake to 21.09%, as stock surges 427% amid Gilead partnership momentum.
GILDTNGXIBBbiotechclinical-stage
GlobeNewswire Inc.GlobeNewswire Inc.··Patentvest

Patent Strength, Not Clinical Data, to Drive GLP-1 Market Leadership

Patent strength, not clinical efficacy, will drive GLP-1 market leadership as clinical outcomes converge. Companies with robust IP portfolios may capture disproportionate market share despite comparable results.
PFELLYNVORHHBYAZN+2GLP-1 drugsoral small-molecule
GlobeNewswire Inc.GlobeNewswire Inc.··Bcc Research

Advanced Drug Delivery Systems Market Set to Reach $487B by 2030

Advanced drug delivery systems market projected to grow from $299.6B (2025) to $487.4B (2030), driven by chronic diseases, nanotechnology breakthroughs, and oncology applications.
AMGNBMYCELGrJNJPFE+3personalized medicineAsia-Pacific
BenzingaBenzinga··Vandana Singh

Gilead to Acquire Oncology-Focused Arcellx in $7.8B Cash Deal

Gilead acquires oncology firm Arcellx for $7.8 billion in cash, adding CAR T-cell cancer therapy to its pipeline. Deal expected to close Q4 2024.
GILDACLXacquisitionM&A
Investing.comInvesting.com··Timothy Fries

Gilead to Acquire Arcellx for $7.8B, Expanding CAR-T Therapy Portfolio

Gilead acquires Arcellx for $7.8B to expand CAR-T therapy portfolio, strengthening oncology pipeline and cell therapy capabilities.
GILDACLXacquisitionFDA approval
BenzingaBenzinga··Vandana Singh

Gilead to Acquire Arcellx for $7.8B to Expand CAR-T Oncology Portfolio

Gilead acquires Arcellx for $7.8B to gain CAR-T therapy anito-cel for multiple myeloma, with FDA approval expected by late 2026.
GILDACLXacquisitionFDA approval